MONALISA: A Privacy-Preserving Infrastructure Supporting Liquid Biopsies to Monitor Relapsed Neuroblastoma

The survival rate for high-risk neuroblastoma remains below 50%. Current monitoring methods are costly, invasive, and stressful for patients. MONALISA will evaluate liquid biopsies as a minimally invasive alternative, to enable frequent sampling and consequently early detection of genetic tumour markers. MONALISA leverages an advanced privacy-preserving data management infrastructure, including the SIOPEN BIOPORTAL, the EUPID Services, and patient reported outcome measures, providing a model for other paediatric cancers.